​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 45 Wall Street analysts, predicts a 12-month average price target of $948.83, with a high of $1,195.00 and a low of $695.00. This represents a 66.78% increase from the last price of $568.91.

$550 $680 $810 $940 $1 $1 High: $1195 Avg: $948.83 Low: $695 Last Closed Price: $568.91

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 45 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 34 Buy (75.56%), 11 Hold (24.44%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 45 11 34 0 Strong Sell Sell Hold Buy Strong Buy

REGN Price Target Upside V Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals66.78%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts2330
Avg Price Target$772.50$816.00$1.12K
Last Closing Price$568.91$568.91$568.91
Upside/Downside35.79%43.43%96.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 257126-126
Mar, 257127-127
Feb, 256118-126
Jan, 257128-128
Dec, 247127-127
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 22, 2025Carter GouldCantor Fitzgerald$695.00$585.4918.70%22.16%
Apr 22, 2025John NewmanCanaccord Genuity$850.00$585.4945.18%49.41%
Mar 14, 2025BMO Capital$903.00$666.8735.41%58.72%
Nov 01, 2024Evan David SeigermanBMO Capital$1.19K$843.6041.06%109.17%
Nov 01, 2024Christopher RaymondPiper Sandler$1.20K$843.6041.65%110.05%
Nov 01, 2024Andrew BerensLeerink Partners$880.00$843.604.31%54.68%
Oct 31, 2024Cory KasimovEvercore ISI$1.17K$838.2039.58%105.66%
Oct 24, 2024Cory KasimovEvercore ISI$1.18K$941.3924.82%106.54%
Oct 23, 2024Mohit BansalWells Fargo$1.05K$962.349.11%84.56%
Sep 24, 2024Thomas KleeTruist Financial$1.20K$1.09K9.89%110.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 22, 2025Cantor FitzgeraldNeutralOverweightupgrade
Nov 13, 2024CitigroupNeutralinitialise
Nov 01, 2024Leerink PartnersMarket PerformMarket Performhold
Oct 29, 2024Piper SandlerOverweightOverweighthold
Oct 24, 2024Evercore ISIOutperformOutperformhold
Oct 23, 2024SusquehannaNeutralNeutralhold
Oct 23, 2024Cowen & Co.BuyBuyhold
Oct 23, 2024Wells FargoOverweightOverweighthold
Oct 04, 2024Wells FargoMarket PerformMarket Performhold
Sep 27, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$25 $36 $47 $58 $69 $80 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$32.65$76.40$40.51$37.05$40.90----
Avg Forecast$30.33$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$31.59$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Low Forecast$28.62$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Surprise %7.65%6.82%-4.91%-13.07%-9.15%----

Revenue Forecast

$5B $8B $11B $14B $17B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.50B$16.07B$12.17B$13.12B$14.20B----
Avg Forecast$8.50B$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$8.77B$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Low Forecast$8.13B$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Surprise %0.00%2.39%2.62%1.37%0.15%----

Net Income Forecast

$2B $3B $5B $6B $8B $9B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.51B$8.08B$4.34B$3.95B$4.41B----
Avg Forecast$2.99B$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$3.59B$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Low Forecast$2.39B$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Surprise %17.57%10.75%-3.36%--14.28%----

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 45 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 34 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 45 Wall Street analysts, averages $948.83 over the next 12 months. The price target range spans from $695 at the low end to $1.2K at the high end, suggesting a potential 66.78% change from the previous closing price of $568.91.

How does Regeneron Pharmaceuticals stock forecast compare to its benchmarks?

Regeneron Pharmaceuticals's stock forecast shows a 66.78% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and underperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • April 2025: 26.92% Strong Buy, 46.15% Buy, 23.08% Hold, 0% Sell, 3.85% Strong Sell.
  • March 2025: 25.93% Strong Buy, 44.44% Buy, 25.93% Hold, 0% Sell, 3.70% Strong Sell.
  • February 2025: 23.08% Strong Buy, 42.31% Buy, 30.77% Hold, 0% Sell, 3.85% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $44.51, marking a 8.83% increase from the reported $40.9 in 2024. Estimates for the following years are $48.41 in 2026, $56.23 in 2027, and $61.14 in 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $14.63B, reflecting a 3.00% increase from the reported $14.2B in 2024. The forecast for 2026 is $15.52B, followed by $17.22B for 2027, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

Regeneron Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $4.36B, representing a -1.23% decrease from the reported $4.41B in 2024. Projections indicate $4.65B in 2026, $5.3B in 2027, and $6.95B in 2028.